Brazil approves Sandoz-marketed Owozy for type 2 diabetes, with launch planned in late 2026.
Brazil, Canada and India are some of the first countries where the patents to GLP-1 drugs expire.
Keystone-SDA
Generic drug manufacturer Sandoz is continuing to expand its presence in the market for novel GLP-1 diabetes treatments. The Basel-based company has confirmed that a new semaglutide generic has been granted marketing authorisation in Brazil, according to a press release issued on Wednesday.
Generated with artificial intelligence.
This content was published on
Sun Pharma receives ANVISA approval to launch semaglutide in Brazil, expanding diabetes treatment options in a $413 million…
El nuevo fármaco con semaglutida llegará al mercado brasileño en las próximas semanas tras vencer la patente del medicamento…
El medicamento se comercializará bajo el nombre Ozivy y llegará al mercado brasileño “en unas pocas semanas”.
Sun Pharma gains ANVISA approval to launch semaglutide in Brazil, partnering with Hypera Pharma for diabetes treatment.
South Africa is now the second market, after India, where the company has secured clearance for a generic semaglutide injection
Em parceria com laboratório Adalvo, Sandoz ingressa no mercado de semaglutida com Owozy
Em parceria com laboratório Adalvo, Sandoz ingressa no mercado de semaglutida com Owozy
